Protocols
18 protocol(s) meet the specified criteria
Disease Site: Multiple Myeloma
Protocol No.TitleStatus
10-CBAA multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indicationsOpen
14-1999Biomarker-Based Radiation Dosimetry ProjectOpen
54767414MMY2004Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell TransplantationOpen
A061202A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based TherapyOpen
BMA117159A Phase I Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Subjects with Relapsed/Refractory Multiple Myeloma and Other Advanced Hematologic malignancies Expressing BCMAOpen
BMT-CTN-1202Prospective Multi-Center Cohort for the Evaluation of Biomarkers Predicting Risk of Complications and Mortality Following Allogeneic HCTOpen
BMT-CTN-1302Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib after Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple MyelomaOpen
COG-ACCL1131A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)Open
DFCI10-106A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age (IFM/DFCI 2009).Open
LCCC0824Tissue Procurement For Hematolymphoid ConditionsOpen
LCCC0905Graft-Versus-Host Disease Solid Tissue ProcurementOpen
LCCC1314A phase II, placebo-controlled, double-blind, randomized trial of pregabalin for the prophylaxis of granulocyte colony stimulating factor (GCSF)-induced bone painOpen
LCCC1341Arterial stiffness in children who recently completed cancer therapy Open
LCCC1512Evaluation of the accuracy of new-generation pedometers in older adult patients with advanced cancers Open
LCCC1535Understanding Treatment Decision-making and Psychological Distress in Patients with Advanced CancerOpen
LCCC1538Geriatric Assessment Reporting in Real Time (GARRT) in non-electively hospitalized older cancer patients: feasibility, impact, and clinician acceptance.Open
LCCC1610Integrated Systems for the Analysis of Circulating Multiple Myeloma Cells (CMMCs)Open
S1304A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease”.Open (affiliates only)